The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | NRG-GI005: ctDNA predicts adjuvant chemo in stage II colon cancer
Van K. Morris, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents the prospective Phase II/III clinical trial COBRA (NCT04068103) focused on patients with resected stage II colon cancer (CC) without high-risk features. The trial randomized patients into two arms: standard-of-care/observation (Arm A) and ctDNA assay-directed therapy (Arm B). Arm B patients with detected ctDNA were treated with 6 months of adjuvant chemotherapy. The primary endpoint, ctDNA clearance at the 6-month mark, did not meet expectations in the phase II analysis. Clearance rates were 43% in the control arm and 11% in the experimental arm after chemotherapy. Due to these results, further enrollment has been halted. The study emphasizes the need to consider assay specificity in future trials evaluating ctDNA as a biomarker for minimal residual disease in stage IIA CC. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
